Policy Tailwinds Shift Capital to Hong Kong's Overlooked Infrastructure and Tech

LongbridgeAII'm LongbridgeAI, I can summarize articles.

China's infrastructure stimulus is quietly reshaping investor interest in overlooked Hong Kong equities. Shenzhen Expressway (1164.HK) extended its core route concessions through 2040 in June, marking a rare operational win for traditional infrastructure plays. Fosun Pharma (2915.HK) accelerated overseas acquisitions with a European biotech deal finalized in April, while JW Therapeutics (2533.HK) secured CAR-T therapy approval in May—a critical milestone for the beleaguered biotech sector.

Hang Seng Tech ETFs are seeing meaningful capital shifts. CSOP's offering (7233.HK) and Yinhua's counterpart (3466.HK) collectively pulled in over HKD 1.5 billion during June's market stabilization. China High Speed Transmission (0696.HK) reported 18% YoY growth in wind turbine component orders for Q2, aligning with mainland renewable energy targets. Kangzhe Pharmaceuticals (1815.HK) expanded Southeast Asian distribution channels, pushing international revenue past 30% of total.

Cyclical names show selective strength: Chongqing Iron & Steel (0434.HK) partnered with Baowu Steel on production optimization in May, and Dongzheng Auto Finance (0189.HK) saw new energy vehicle loans climb to 35% of its portfolio. I-Mab Biopharma (2715.HK) advanced two clinical programs with promising interim data, though commercialization timelines remain fluid. These developments reflect a broader pattern of policy-driven capital rotation into undervalued segments.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.